A. Slominski, A. Pisarchik, B. Zbytek, D. J. Tobin, S. Kauser and J. Wortsman. Functional activity of serotoninergic and me- latoninergic systems expressed in the skin. Journal of Cellular Physiology, 2003, 196(1): 144-153.
被以下文章引用:
-
标题:
5-羟色胺与硬皮病Serotonin and Scleroderma
作者:
黄建国, 龚启英, 黄朝頔, 李桂明
关键字:
5-羟色胺, 硬皮病Serotonin; Scleroderma
期刊名称:
《Hans Journal of Medical Cosmetology》, Vol.1 No.1, 2013-10-14
摘要:
硬皮病是自身免疫性疾病之一，以血管功能障碍、炎症和皮肤硬化为特征。5-羟色胺(5-HT)作为血管活性胺类物质，炎症介质能刺激真皮成纤维细胞增殖；5-HT/5-HT2B信号通过调控血管损伤和血小板活性从而与皮肤组织纤维化有关联。临床上采用5-HT3受体抑制剂托烷司琼(tropisetron)治疗硬皮病患者取得明显效果。研究5-HT与硬皮病的关系对治疗硬皮病将开辟一条新的途径。
Scleroderma is one of the autoimmune diseases characterized by inflammation, vascular dysfunction and skin sclerosis. As the vasoactive amine substances and inflammatory mediators, serotonin (5-HT) can stimulate the dermal fibroblast proliferation; 5-HT/5-HT2B signal are associated with skin tissue fibrosis through regulating vascular injury and platelet activity. The clinical application of tropisetron (5-HT3 receptor inhibitor) obtains obvious effects in the treatment of patients with scleroderma. Study on the relationship between 5-HT and scleroderma will inaugurate a new way for the treatment of scleroderma.